France Newborn Screening Market Size & Outlook, 2023-2030
France newborn screening market, 2018-2030 (US$M)
Related Markets
France newborn screening market highlights
- The France newborn screening market generated a revenue of USD 32.2 million in 2023 and is expected to reach USD 50.2 million by 2030.
- The France market is expected to grow at a CAGR of 6.6% from 2024 to 2030.
- In terms of segment, tandem mass spectrometry was the largest revenue generating technology in 2023.
- Electrophoresis is the most lucrative technology segment registering the fastest growth during the forecast period.
Newborn screening market data book summary
| Market revenue in 2023 | USD 32.2 million |
| Market revenue in 2030 | USD 50.2 million |
| Growth rate | 6.6% (CAGR from 2023 to 2030) |
| Largest segment | Tandem mass spectrometry |
| Fastest growing segment | Electrophoresis |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Tandem Mass Spectrometry, Pulse Oximetry, Enzyme-based Assay, DNA Assays, Electrophoresis |
| Key market players worldwide | Bio-Rad Laboratories Inc, Agilent Technologies, Agilent Technologies Inc, Covidien, Masimo Corp, Waters Corp, Natus Medical, GE HealthCare Technologies Inc Common Stock, PerkinElmer, Danaher Corp |
Other key industry trends
- In terms of revenue, France accounted for 4.0% of the global newborn screening market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK newborn screening market is projected to lead the regional market in terms of revenue in 2030.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 36.8 million by 2030.
Tandem mass spectrometry was the largest segment with a revenue share of 24.53% in 2023. Horizon Databook has segmented the France newborn screening market based on tandem mass spectrometry, pulse oximetry, enzyme-based assay, dna assays, electrophoresis covering the revenue growth of each sub-segment from 2018 to 2030.
French government is actively involved in the screening of newborns for presence of any abnormalities. The national program conducts over 1 million tests annually on more than 0.8 million newborns. According to statistics, the mortality rate is about 3.37 in 1,000 babies accounting for 34% of the neonate population.
Recently, a new mode for cystic fibrosis screening was developed by France, which can also be implemented in other countries. The Association Francaise pour le Depistage et la Prevention des Handicaps de l’Enfant officially works on reporting and maintaining information regarding newborn screening working at the regional level.
Haute autorité de santé (HAS)/French National Authority for Health, in 2011, recommended the inclusion of medium-chain acly-CoA dehydrogenase (MCAD) testing for the population of France by utilizing tandem mass spectrometry. Other tests carried out for the region include cystic fibrosis, hyperplasia, congenital hypothyroidism, phenylketonuria, and sickle cell disease.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Newborn Screening Market Scope
Newborn Screening Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France newborn screening market size, by technology, 2018-2030 (US$M)
France Newborn Screening Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
